IL18 and neoplasm: Similarly, Kunert et al. engineered T cells with a melanoma-specific TCR and murine IL-18 under the control of a nuclear-factor of activated T-cell (NFAT)-sensitive promoter; the cells produced IL-18 and consequently enhanced levels of IFN-γ after exposure to antigen-positive tumor cells.